Arterial Hypertension

An antihypertensive drug given subcutaneously every 6 months 

Hypertension affects 30-45% of adults and is the most important modifiable risk factor for cardiovascular disease, primarily stroke and myocardial infarction.

The global burden of disease is heavy, with a global prevalence of over one billion and around 9 million deaths attributed to hypertension annually.

Currently available pharmacological therapies only achieve target blood pressure in a minority of cases, largely due to the patient not taking their medication properly. Poor adherence to oral antihypertensive drugs is associated with poor cardiovascular outcomes and is prevalent at all stages of the disease.

Thus, the development of new approaches to treat hypertension and overcome the limitations of current therapies is a key unmet need.

We are conducting a clinical study to assess the efficacy and safety of the drug in participants with mild to moderate hypertension. We are conducting this study to support the development of an investigational blood pressure injection drug that will be revolutionary in healthcare.

To participate, you must:

• Be between 18 and 75 years old
• Have untreated hypertension or is under stable treatment with 1 or more antihypertensive drugs

You will be given reimbursement for study-related expenses when you participate in the clinical study and you will be surrounded by a medical team throughout the process.